Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Buy
82
SLNO Quote, Financials, Valuation and Earnings
Last price:
$73.57
Seasonality move
:
2.33%
Day range:
$66.50 - $71.29
52-week range:
$36.61 - $73.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3,503.72x
P/B ratio:
12.77x
Volume:
1.9M
Avg. volume:
1.5M
1-year change:
64.52%
Market cap:
$3.1B
Revenue:
--
EPS (TTM):
-$4.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics
|
-- | -- | -- | -- | $102.13 |
|
AARD
Aardvark Therapeutics
|
-- | -$0.67 | -- | -- | $32.33 |
|
CVM
CEL-SCI
|
-- | -- | -- | -- | $8.00 |
|
KRYS
Krystal Biotech
|
$99.2M | $1.39 | 121.14% | 497.44% | $214.80 |
|
LEGN
Legend Biotech
|
$192.6M | -$0.29 | 104.21% | -8.33% | $78.01 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics
|
$68.26 | $102.13 | $3.1B | -- | $0.00 | 0% | 3,503.72x |
|
AARD
Aardvark Therapeutics
|
$8.29 | $32.33 | $177.3M | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI
|
$0.22 | $8.00 | $16.9M | -- | $0.00 | 0% | -- |
|
KRYS
Krystal Biotech
|
$174.58 | $214.80 | $5B | 58.39x | $0.00 | 0% | 17.85x |
|
LEGN
Legend Biotech
|
$31.52 | $78.01 | $5.8B | -- | $0.00 | 0% | 9.19x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLNO
Soleno Therapeutics
|
-- | -2.069 | -- | -- |
|
AARD
Aardvark Therapeutics
|
-- | 0.000 | -- | -- |
|
CVM
CEL-SCI
|
-- | 1.752 | -- | -- |
|
KRYS
Krystal Biotech
|
-- | 1.671 | -- | 6.89x |
|
LEGN
Legend Biotech
|
22.45% | 1.522 | 5.04% | 4.49x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics
|
-- | -$58.8M | -- | -- | -- | -$24M |
|
AARD
Aardvark Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
CVM
CEL-SCI
|
-- | -$6.9M | -- | -- | -- | -$4.2M |
|
KRYS
Krystal Biotech
|
$86.2M | $41.4M | 10.49% | 10.49% | 45.4% | $52M |
|
LEGN
Legend Biotech
|
$112.6M | -$74.4M | -12.31% | -15.44% | 24.48% | -$84.5M |
Soleno Therapeutics vs. Competitors
-
Which has Higher Returns SLNO or AARD?
Aardvark Therapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of --. Soleno Therapeutics's return on equity of -- beat Aardvark Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics-- -$1.27 -- AARDAardvark Therapeutics-- -- -- -
What do Analysts Say About SLNO or AARD?
Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 49.61%. On the other hand Aardvark Therapeutics has an analysts' consensus of $32.33 which suggests that it could grow by 290.03%. Given that Aardvark Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Aardvark Therapeutics is more attractive than Soleno Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics5 0 0 AARDAardvark Therapeutics2 0 0 -
Is SLNO or AARD More Risky?
Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Aardvark Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SLNO or AARD?
Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aardvark Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Aardvark Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or AARD?
Soleno Therapeutics quarterly revenues are --, which are smaller than Aardvark Therapeutics quarterly revenues of --. Soleno Therapeutics's net income of -$56M is higher than Aardvark Therapeutics's net income of --. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Aardvark Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,503.72x versus -- for Aardvark Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics3,503.72x -- -- -$56M AARDAardvark Therapeutics-- -- -- --
-
Which has Higher Returns SLNO or CVM?
CEL-SCI has a net margin of -- compared to Soleno Therapeutics's net margin of --. Soleno Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics-- -$1.27 -- CVMCEL-SCI-- -$0.11 -- -
What do Analysts Say About SLNO or CVM?
Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 49.61%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 3544.65%. Given that CEL-SCI has higher upside potential than Soleno Therapeutics, analysts believe CEL-SCI is more attractive than Soleno Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics5 0 0 CVMCEL-SCI1 0 0 -
Is SLNO or CVM More Risky?
Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.939%.
-
Which is a Better Dividend Stock SLNO or CVM?
Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or CVM?
Soleno Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Soleno Therapeutics's net income of -$56M is lower than CEL-SCI's net income of -$7.1M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,503.72x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics3,503.72x -- -- -$56M CVMCEL-SCI-- -- -- -$7.1M
-
Which has Higher Returns SLNO or KRYS?
Krystal Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 49.9%. Soleno Therapeutics's return on equity of -- beat Krystal Biotech's return on equity of 10.49%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics-- -$1.27 -- KRYSKrystal Biotech94.57% $1.52 $946.4M -
What do Analysts Say About SLNO or KRYS?
Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 49.61%. On the other hand Krystal Biotech has an analysts' consensus of $214.80 which suggests that it could grow by 23.04%. Given that Soleno Therapeutics has higher upside potential than Krystal Biotech, analysts believe Soleno Therapeutics is more attractive than Krystal Biotech.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics5 0 0 KRYSKrystal Biotech8 1 0 -
Is SLNO or KRYS More Risky?
Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.751, suggesting its less volatile than the S&P 500 by 24.867%.
-
Which is a Better Dividend Stock SLNO or KRYS?
Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or KRYS?
Soleno Therapeutics quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $91.1M. Soleno Therapeutics's net income of -$56M is lower than Krystal Biotech's net income of $45.5M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 58.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,503.72x versus 17.85x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics3,503.72x -- -- -$56M KRYSKrystal Biotech17.85x 58.39x $91.1M $45.5M
-
Which has Higher Returns SLNO or LEGN?
Legend Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 14.09%. Soleno Therapeutics's return on equity of -- beat Legend Biotech's return on equity of -15.44%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics-- -$1.27 -- LEGNLegend Biotech60.37% $0.14 $1.3B -
What do Analysts Say About SLNO or LEGN?
Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 49.61%. On the other hand Legend Biotech has an analysts' consensus of $78.01 which suggests that it could grow by 147.5%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics5 0 0 LEGNLegend Biotech11 2 0 -
Is SLNO or LEGN More Risky?
Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Legend Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SLNO or LEGN?
Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legend Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Legend Biotech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or LEGN?
Soleno Therapeutics quarterly revenues are --, which are smaller than Legend Biotech quarterly revenues of $186.5M. Soleno Therapeutics's net income of -$56M is lower than Legend Biotech's net income of $26.3M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Legend Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,503.72x versus 9.19x for Legend Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics3,503.72x -- -- -$56M LEGNLegend Biotech9.19x -- $186.5M $26.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
